Free radicals and the pathobiology of brain dopamine systems

Neurochemistry International

Volumn 32, Issue 2, 1997, Pages 117-131

  Cadet, Jean Lud ^a   Brannock, Christie ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CATECHOLAMINE; DOPAMINE; FREE RADICAL; METHAMPHETAMINE; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

DOPAMINE BRAIN LEVEL; HUMAN; MONOAMINERGIC SYSTEM; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCAVENGING SYSTEM;

EID: 0031200869     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(97)00031-4     Document Type: Article

References (131)

1. Adams, J. D., Klaidman, L. K., Odunze, I. N., Shen, H. C., & Miller, C. A. (1991). Alzheimer's and Parkinson's disease: Brain levels of glutathione, glutathione disulfide, and vitamin E. Mol. Chem. Neuropathol., 14, 213-226.
2. Agid, Y., Javoy-Agid, F., & Ruberg, M. (1987). Biochemistry of neurotransmitters in Parkinson's disease. In Movement Disorders 2, eds C. D. Marsden and S. Fahn, pp. 166-230. Butterworths, London.
3. Ali, S. F., David, S. N., Newport, G. D., Cadet, J. L., & Slikker, W. J. (1994). MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence form measures of reactive oxygen species and striatal dopamine levels. Synapse, 18, 27-34.
4. Ambani, L. M., Van Woert, M. H., & Murphy, S. (1975). Brain peroxidase and catalase in Parkinson's disease. Arch. Neurol., 32, 114-118.
5. Baldwin, H. A., Colado, M. I., Murry, T. K., De Souza, R. J., & Green, A. R. (1993). Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br. J. Pharmacol., 108, 590-596.
6. Banati, R. B., Gehrmann, J., Schubert, P., & Kreutzberg, G. W. (1993). Cytotoxicity of microglia. Glia, 7, 111-118.
7. Battaglia, G., Yeh, S. Y., O'Hearn, E., Molliner, M. E., Kuhar, M. J., & De Souza, E. B. (1987). 3,4-methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain. Quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther., 242, 911-916.
8. Beckman, J. S. (1991). The double-edged role of nitric oxide in brain and superoxide-mediated injury. J. Dev. Physiol., 15, 53-59.
9. Bennett, B. A., Hyde, C. E., Pecore, J. R., & Coldfelter, J. E. (1993). Differing neurotoxic potencies of methamphetamine, mazindol, and cocaine in mesencephalic cultures. J. Neurochem., 60, 1444-1452.
10. Ben-Shachar, D., & Youdim, M. B. H. (1991). Intranigral iron injection induces behavioral and biochemical "Parkinsonism" in rats. J. Neurochem, 57, 2133-2135.
11. Berger, K., Przedborski, S., & Cadet, J. L. (1990). Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res. Bull., 26, 301-307.
12. Bernheimer, R. S., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological and neurochemical correlations. J. Neurol. Sci., 20, 415-455.
13. Breese, G. R., & Taylor, T. D. (1970). Effect of 6-hydroxydopamine on brain norepinephrine and dopamine: evidence for selective degeneration of catecholamine neurons. J. Pharmacol. Exp. Ther., 174, 413-420.
14. Brodkin, J., Malyala, A., & Nash, J. F. (1993). Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol. Biochem. Behav., 45, 647-653.
15. Cadet, J. L. (1988). A unifying hypothesis of movement and madness: involvement of free radicals in disorders of the isodendritic core. Medical Hypotheses, 27, 87-94.
16. Cadet, J. L., Katz, M., Jackson-Lewis, V., & Fahn, S. (1989). Vitamin E attenuates the toxicity of intrastriatal injection of 6-hydroxydopamine (6-OHDA): behavioral and biochemical evidence. Brain Res., 476, 10-15.
17. Cadet, J. L., Ladenheim, B., Baum, I., Carlson, E., & Epstein, C. (1994a). CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA). Brain. Res., 655, 259-262.
18. Cadet, J. L., Ladenheim, B., Hirata, H., Rothman, R., Ali, S., Carlson, E., Epstein, C., & Moran, T. (1995). Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn-superoxide transgenic mice. Synapse, 21, 169-176.
19. Cadet, J. L., Last, R., Kostic, V., Przedborski, S., & Jackson-Lewis, V. (1991). Long-term behavioral and biochemical effects of intrastriatal injections of 6-hydroxydopamine. Brain Res. Bull., 26, 707-713.
20. Cadet, J. L., & Lohr, J. B. (1988). Free radicals and the developmental pathobiology of schizophrenic burnout. Integr. Psychiatry, 5, 40-48.
21. Cadet, J. L., & Lohr, J. B. (1989). Possible involvement of free radicals in neuroleptic-induced movement disorders. Ann. N.Y. Acad. Sci., 570, 176-185.
22. Cadet, J. L., Sheng, P., Ali, S., Rothman, R., Carlson, E., & Epstein, C. (1994b). Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J. Neurochem., 62, 380-383.
23. Cadet, J. L., & Zhu, S. M. (1992). The instrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic nigrostriatal markers in the rat. Brain Res., 595, 316-326.
24. Chance, B., Sies, H., & Boveris, H. (1979). Hydroperoxide metabolism in mammalian organs. Physiol. Rev., 59, 527-605.
25. Chiba, K., Trevor, A. J., Castagnoli, N. Jr. (1984). Metabolism of neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun., 120, 574-578.
26. Chiueh, C. C., Huang, S. J., & Murphy, D. L. (1994). Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. J. Neurol. Transm., 41((suppl)), 189-196.
27. Cohen, G. (1987). Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv. Neurol., 45, 119-125.
28. Cohen, G., & Heikkila, R. E. (1974). The generation of hydrogen peroxide, superoxide radical and hydroxyl radical by hydroxydopamine, dialuric acid, and related cytotoxic agents. J. Biol. Chem., 249, 2447-2452.
29. Cohen, G., Heikkila, R. E., Allis, B., Cabbat, D., Bembiec, D., MacNamee, D., Mytlineou, C., & Winston, B. (1976). Destruction of sympathetic nerve terminals by 6-hydroxydopamine: Protection by L-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol, and n-butanol. J. Pharmacol. Exp. Ther., 199, 336-352.
30. Commins, D. L., Vosmer, G., Virus, R. M., Woolverton, W. L., Schuster, C. R., & Seiden, L. S. (1987). Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in rat brain. J. Pharmacol. Exp. Ther., 241, 338-345.
31. Cubells, J. F., Rayport, S., Rajndron, G., & Sulzer, D. (1994). Methamphetamine neurotoxicity involves vacuolation of endoxytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci., 14, 2260-2271.
32. Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979). Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat. Res., 1, 249-254.
33. Dawson, V. L., Dawson, T. M., Bartley, D. A., Uhl, G. R., & Snyder, S. M. (1993). Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J. Neurosci., 13, 2651-2661.
34. DeVito, M. J., & Wagner, G. C. (1989). Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacol., 28, 1145-1150.
35. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1989). Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem., 52, 381-389.
36. Dexter, D. T., Jenner, P., Schapira, A. H. V., & Marsden, C. D. (1992). Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann Neurol., 32, 94-100.
37. Dexter, D. T., Sian, J., Rose, S., Hindmarsh, J. G., Mann, V. M., Cooper, J. M., Wells, F. R., Daniel, S. E., Lees, A., Schapira, A. H. V., Jenner, P., & Marsden, C. D. (1994). Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol., 35, 38-44.
38. Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1987). Increased nigral iron content in post-mortem parkinsonism brain. Lancet, 11, 219-220.
39. Dickson, D. W., Mattiace, L. A., Kure, K., Hutchins, K., Lyman, W. D., & Brosnan, C. (1991). Biology of disease: microglia in human disease, with an emphasis on acquired immune deficiency syndrome. Lab Invest., 64, 135-156.
40. Dordain, G., Dostert, P., Strolin Beneditti, M., & Rovei, V. (1984). Tetrahydroisoquinoline derivatives and Parkinsonism. In Monoamine oxidase and disease prospect for therapy with reversible inhibitors, eds K. F. Tipton, P. Dostert and M. Strolin Beneditti, pp. 417-426. Academic Press, London.
41. Dostert, P., Strolin Benedetti, M., Della Vedova, F., Alleivi, C., La Croix, R., Dordain, G., Vernay, D., & Durif, F. (1993). Dopamine-derived tetrahydroisoquinolines and Parkinson's Disease. Adv. Neurol., 60, 218-223.
42. Dostert, P., Strolin Benedetti, M., & Dordain, G. (1988). Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases. J. Neurol. Transm., 74, 61-74.
43. Epstein, C. J., Avraham, K. B., Lovett, M., Smith, S., Elroy-Stein, O., Rotman, G., Bry, C., & Groner, Y. (1987). Transgenic mice with increased CuZn-superoxide dismutase activity: Animal model of dosage effects in Down Syndrome. Proc. Natl Acad. Sci. USA, 84, 8044-8048.
44. Fahn, S. (1977). Secondary Parkinsonism. In Scientific Approaches to Clinical Neurology, eds E. S. Godenshohn and S. H. Appel, pp. 1159-1189. Lea and Febiger, Philadelphia.
45. Fahn, S., & Cohen, G. (1992). The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol., 32, 804-812.
46. Fahn, S., Libsch, L. R., & Cutler, R. W. (1971). Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J. Neurol. Sci., 14, 427-455.
47. Frei, B., Englan, L., & Ames, B. N. (1989). Ascorbate is an outstanding antioxidant in human blood plasma. Proc. Natl Acad. Sci. USA 86, 6377-6381.
48. Fridovich, I. (1983). Superoxide radical: an endogenous toxicant. Ann. Rev. Pharmacol., 23, 239-257.
49. Fridovich, I. (1986). Biological effects of the superoxide radical. Arch. Biochem. Biophys., 247, 1-11.
50. Giovanni, A., Liang, L. P., Hastings, T. G., & Zigmond, M. J. (1995). Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: Impact of methamphetamine. J. Neurochem., 64, 1819-1825.
51. Graham, D. G. (1978). Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol., 14, 633-643.
52. Graham, D. G., Tiffany, S. M., Bell, W. R., & Gutknecht, W. F. (1978). Auto-oxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-OH-dopamine, and related compounds towards C300 neuroblastoma cells in vitro. Mol. Pharmacol., 14, 644-653.
53. Guilian, D., & Baker, T. J. (1986). Characterization of ameloid microglia isolated from developing mammalian brain. J. Neurosci., 6, 2163-2178.
54. Guilian, D., & Ingelman, J. E. (1988). Colony-stimulating factors as promoters of ameloid microglia. J. Neurosci., 8, 4707-4717.
55. Halliwell, B., & Gutteridge, J. M. C. (1985). The importance of free radicals and catalytic metal ions in human diseases. Mol. Aspects Med., 8, 89-93.
56. Heikkila, R. E., Hess, A., & Duvoisin, R. C. (1984). Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science, 224, 1451-1453.
57. Heikkila, R. E., Nicklas, W. L., & Vyas, I. (1985). Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implications for the mechanism of 1-methyl-4-phenyl-1,2,3,5,6-tetrahydropyridine toxicity. Neurosci. Lett., 62, 389-394.
58. Hirata, H. H., Ladenheim, B., Carlson, E., Epstein, C., & Cadet, J. L. (1996). Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res., 714, 95-103.
59. Hiramatsu, M., Kumagai, Y., Unger, S. E., & Cho, A. K. (1990). Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther., 254, 251-527.
60. Hirsch, E. C., Brandel, J. P., Galle, P., & Javoy-Agid, Y. (1991). Iron and aluminum increases in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem., 56, 446-451.
61. Hotchkiss, A. J., & Gibb, J. W. (1980). Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J. Pharmacol. Exp. Ther., 214, 257-262.
62. Ikeda, R., Ikeda, S., Yoshimura, T., Kato, K., & Namba, M. (1978). Idiopathic parkinsonism with Lewy-type inclusions in cerebral cortex. A case report. Acta Neuropathol. (Berlin), 41, 165-168.
63. Insel, T. T., Battaglia, G., Johannessen, J. N., Marra, S. & De Souza, E. B. (1989). 3,4-methylenedioxymethamphetamine "Ecstasy" selectively destroys brain serotonin terminals in rhesus monkeys. J. Pharmacol. Exp. Ther., 249, 713-729.
64. Jackson, G. R., Apfell, L., Werrbacch-Perez, K., & Perez-Polo, J. R. (1990). Role of nerve growth factor in oxidant-antioxidant balance and neuronal injury. I. Stimulation of hydrogen peroxide resistance. J. Neurosci. Res., 25, 360-369.
65. Javitch, J. A., D'amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985). Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydro-pyrindine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl Acad. Sci. USA, 82, 2173-2177.
66. Jellinger, K. A., Kienzl, E., Rumpelmaier, G., Parelus, W., Reiderer, P., Stachelberger, H., Youdin, M. B. H., & Ben-Shachar, D. (1993). Iron and ferritin in substantia nigra in Parkinson's Disease. Adv. Neurol., 60, 267-272.
67. Johnson, M., Letter, A. A., Merchant, K., Hanson, G. R., & Gibb, J. W. (1988). Effects of 3,4-methylenedioxymethamphetamine on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. J. Pharmacol. Exp. Ther., 244, 977-982.
68. Kish, S. J., Morito, C., & Hormykiewicz, O. (1985). Glutathione peroxidase activity in Parkinson's disease. Neurosci. Lett., 58, 343-346.
69. Kolb, H., & Kolb-Bachofen, V. (1992). Nitric oxide: a pathogenic factor in autoimmunity. Immunol. Today, 13, 157-160.
70. Kontur, P. J., Won, L. A., Hoffman, P. C., & Heller, A. (1991). Survival of developing dopaminergic neurons in reaggregate tissue culture following treatment with methamphetamine. Neurosci. Lett., 129, 254-258.
71. Ku, H.-H., Brunk, U. T., & Sohal, R. S. (1993). Relationship between mitochondrial superoxide and hydrogen peroxide production and longevity of mammalian species. Free Radical Biol. Med., 15, 621-627.
72. Lafon-Cazal, M., Pietri, S., Culcasi, M., & Bockaert, J. (1993). NMDA-dependent superoxide production and neurotoxicity. Nature, 364, 535-537.
73. Lafon-Cazal, M., Culcasi, M., Gaven, F., Pietri, S., & Bockaert, J. (1993). Nitric oxide, superoxide, and peroxynitrite: putative mediators of NMDA-induced cell death in cerebellar granule cells. Neuropharmacol., 32, 1259-1266.
74. Langston, J. W., Ballard, P. A., Tetrud, J. W., & Irwin, I. (1983). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979-980.
75. Langston, J. W., Langston, E. B., & Irwin, I. (1984). MPTP-induced parkinsonism in human and nonhuman primates - Clinical and experimental aspects. Acta. Neurol. Scand., 70(suppl 100), 49-54.
76. Lipton, S., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., & Chen, H. V. (1993). A redox-based mechanism for the neuroprotective and neuro-destructive effects of nitric oxide and related nitroso-compounds. Nature, 364, 626-632.
77. Logan, B. J., Laverty, R., Sanderson, W. D., & Yee, Y. B. (1988). Differences between rats and mice in MDMA (methylenedioxymethamphetamine) neurotoxicity. Eur. J. Pharmacol., 152, 227-234.
78. Markey, S. P., Johannessen, J. N., Chiueh, C. C., Burns, R. S., & Herkenham, M. A. (1984). Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature, 311, 464-467.
79. Marshall, J. F., O'Dell, S. J., & Weihmuller, F. B. (1993). Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity. J. Neural Transm., 91, 241-254.
80. Marsden, C. D. (1990). Parkinson's disease. Lancet, 335, 948-952.
81. Martilla, R. J., Lorentz, H., & Rinne, U. K. (1988). Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and the basal nucleus. J. Neurol. Sci., 86, 321-331.
82. Maruyama, W., Dostert, P., Matsubara, K., & Naoi, M. (1995). N-methyl (R) salsolinol produces hydroxyl radicals: involvement to neurotoxicity. Free Rad. Biol. Med., 19, 67-75.
83. Maruyama, W., Nakahara, D., Dostert, P., Takahashi, T., & Naoi, M. (1995b). Dopamine derived isoquinolines as dopaminergic neurotoxins and oxidative stress. In Alzheimer's and Parkinson's Diseases: Recent Development, eds I. Hanin and A. Fisher, pp. 575-581. Plenum Press, New York.
84. Maveli, I., Rigo, A., Federico, R., Ciriolo, M. R., & Rotilio, G. (1982). Superoxide dismutase, glutathione peroxidase and catalase in developing rat brain. Biochem. J., 204, 535-540.
85. McGeer, P. L., Itagaki, S., Akiyama, H., & McGeer, E. G. (1988). Rate of cell death in Parkinsonism indicates active neuropathological process. Ann. Neurol., 24, 574-576.
86. McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease. Neurology, 38, 1285-1291.
87. Mellow-Filho, A. C., & Meneghini, R. (1984). In vivo formation of single strand breaks in DNA by hydrogen peroxide is mediated by the Haber-Weiss reaction. Biochem. Biophys. Acta., 781, 56-63.
88. Moncada, S., Palmer, R. M. J., & Higgs, E. A. (1991). Nitric oxide physiology, pathophysiology and pharmacology. Pharmacol. Rev., 43, 109-142.
89. Nakayama, M., Loyama, T., & Yamashita, I. (1992). Long-lasting decreases in dopamine uptake sites following repeated administration of methamphetamine in the rat striatum. Brain Res., 601, 209-212.
90. Nash, J. F., & Nichols, D. E. (1991). Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogs. Eur. J. Pharmacol., 200, 53-58.
91. Nathan, C. (1992). Nitric oxide as a secretory product of mammalian cells. FASEB J., 6, 3051-3064.
92. Niva, T., Takeda, N., Yoshizumi, H., Tatematsu, A., Yoshida, M., Dostert, P., Naoi, M., & Nagatsu, T. (1991). Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydro-isoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydro-isofquinoline, novel endogenous amines in parkinsonian and normal human brains. Biochem. Biophys. Res. Commun., 177, 603-609.
93. O'Callaghan, J. P., & Miller, D. E. (1994). Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther., 270, 741-751.
94. Oestreicher, E., Sengstock, G. J., Reiderer, P., Olanow, C. W., Dunn, A. J., & Nrendash, G. (1994). Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res., 660, 8-18.
95. O'Hearn, E., Battaglia, G., De Souza, E. B., Kuhar, M. J., & Molliver, M. E. (1988). Methylenedioxyamphetamine and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity. J. Neurosci., 8, 2788-2903.
96. Perumal, A. S., Tordzro, W. K., Katz, M., Jackson-Lewis, V., Cooper, T. B., Fahn, S., & Cadet, J. L. (1989). Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain. Brain Res., 504, 139-141.
97. Pitkanen, S., & Robinson, B. H. (1996). Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J. Clin. Invest., 98, 345-351.
98. Preston, K. L., Wagner, G. C., Schuster, C. R., & Seiden, L. S. (1985). Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain. Brain Res., 338, 243-248.
99. Pu, C., Broening, H. W., & Vorhees, C. (1996). Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex. Synapse, 23, 328-334.
100. Radi, R., Beckman, J. S., Bush, K. M., & Freeman, B. A. (1991). Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem., 266, 4244-4250.
101. Reiderer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M.B.H. (1989). Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J. Neurochem., 52, 515-520.
102. Ricaurte, G. A., Schuster, C. R., & Seiden, L. S. (1980). Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: Regional study. Brain Res., 193, 153-163.
103. Ricaurte, G. A., Langston, J. W., DeLanney, L. E., Irwin, I., Peroutka, S. J., & Forno, L. S. (1986). Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A neurochemical and morphological reassessment. Brain Res., 376(1), 117-124.
104. Reichmann, H., Joanetsky, B., & Reiderer, P. (1995). Iron-dependent enzymes in Parkinson's disease. J. Neural. Transm., 46(Suppl), 157-164.
105. Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., Rahmani, Z., Krizus, A., McKenna-Yasek, D., Cayabyab, A., Gaston, S. M., Berger, R., Tanzi, R. E., Halperin, J. J., Herztfedlt, B., Van Denbergh, R., Hung, W.-Y., Bird, T., Deng, G., Mulder, D. W., Smyth, C., Laing, N. G., Soriano, E., Pericak-Vance, M. A., Haines, J., Rouleau, G. A., Gusella, J. S., Horvitz, H. R., & Brown, R. H. Jr. (1993). Mutations in CU/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362, 59-62.
106. Saggu, H., Cooksey, J., Dexter, D., Wells, F. R., Lees, A., Jenner, P., & Marsden, C. D. (1989). A selective increase in particulate superoxide dismutase activity in Parkinsonian substantia nigra. J. Neurochem., 53, 692-697.
107. Sandler, M., Bonham Carter, S., Hunter, K. R., & Stern, G. M. (1975). Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-dopa in man. Nature, 241, 439-443.
108. Schapira, A. H. V. (1994). Evidence for mitochondrial dysfunction in Parkinson's disease a critical appraisal. Movement Disorders, 9, 125-138.
109. Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. M. (1990). Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem., 54, 823-827.
110. Schmidt, C. J. (1987). Neurotoxicity of the psychedelic amphetamine methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther., 240, 1-7.
111. Schraufstatter, I. U., Hinshaw, D. B., Hyslop, P. A., Spragg, R. G., & Conchrane, C. G. (1986). Oxidant injury of cells: DNA strandbreaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J. Clin. Invest., 77, 1312-1320.
112. Schraufstatter, I. U., Hyslop, P. A., Minshaw, D. B., Hyslop, P. A., Spragg, R. G., Sklar, L. A., & Conchrane, C. G. (1986). Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADP-ribose) polymerase. Proc. Natl Sci. USA, 83, 4908-4912.
113. Seiden, L. S., & Vosmer, G. (1984). Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol. Biochem. Behav., 21, 29-31.
114. Sengstock, G., Olanow, C. W., Menzies, R., Dunn, A. J., & Arendash, G. (1993). Infusion of iron into the rats substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J. Neurosci. Res., 35, 67-82.
115. Sengstock, G., Olanow, C. W., Dunn, A. J., Barone, S., & Arendash, G. (1994). Striatal dopaminergic markers, nigral volume and rotational behavior following iron infusion into the rats substantia nigra. Exp. Neurol., 130, 82-94.
116. Sheng, P., Cerutti, C., & Cadet, J. L. (1994). Methamphetamine (METH) causes reactive gliosis in vitro: Attenuation by the ADP-ribosylation (ADPR) inhibitor, benzamide. Life Sci., 55, 51-54.
117. Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Jenner, P., & Marsden, C. D. (1994). Glutathione related enzymes in brain in Parkinson's disease. Ann. Neurol., 36, 356-361.
118. Sofic, E., Paulus, W., Jellinger, K., Reiderer, P., & Youdim, M. B. H. (1991). Selective increase in iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem., 56, 978-982.
119. Sofic, E., Reiderer, P., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G., & Youdim, M. B. (1988). Increases iron (III) and total iron content in post-mortem substantia nigra of parkinsonian brain. J. Neural Transm., 74, 199-205.
120. Sonsalla, P. K., Nicklas, W. J., & Heikkila, R. E. (1989). Role for excitatory amino acids in methamphetamine-induced dopaminergic toxicity. Science, 243, 398-400.
121. Sonsalla, P. K., Riordan, D. E., & Heikkila, R. E. (1991). Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther., 256, 506-512.
122. Stadtman, E. R. (1993). Oxidation of free amino acid residues in proteins by radiolysis and by metal catalyzed reactions. Ann. Rev. Biochem., 62, 797-821.
123. Steranka, L. R., & Sanders-Bush, E. (1980). Long-term effects of continuous exposure to amphetamine in bran dopamine concentration and synaptosomal uptake in mice. Eur. J. Pharmacol., 65, 439-443.
124. Stone, D. M., Stahl, D. C., Hanson, G. R., & Gibb, J. W. (1986). The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur. J. Pharmacol., 128, 41-48.
125. Wagner, G. C., Ricaurte, G. A., Seiden, L. S., Schuster, C. R., Miller, R. J., & Westley, J. (1980). Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res., 181, 151-160.
126. Wagner, G. C., Carelli, R. M., & Jarvis, M. F. (1985). Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res. Comm. Chem. Pathol. Pharmacol., 47, 221-228.
127. Weihmuller, F. B., O'Dell, S. J., & Marshall, J. F. (1992). MK-801 protection against methamphetamine-induced striatal dopamine terminal injury is associated with attenuated dopamine overflow. Synapse 11, 155-163.
128. Wesemann, W., Blaschka, S., Salbach, M., Crote, C., Clement, H. W., & Riederer, P. (1994). Intranigral injected iron progressively reduces striatal dopamine metabolism. J. Neural Transm. (PD-D-Section) 8, 209-214.
129. Yoshida, E., Mokuno, K., Aoki, S., Mokuno, K., Aoki, S., Takahashi, A., Riku, S., Murayama, T., Yanagi, T., & Kato, K. (1994). Cerebrospinal fluid levels of superoxide dismutase in neurological diseases detected by sensitive enzyme immunoassays. J. Neurological Sci., 124, 25-31.
130. Youdim, M. B. H., Ben-Shachar, D., & Riederer, P. (1994). The enigma of neuromelanin in Parkinson's disease substantia nigra. J. Neural Transm., 43(Suppl), 113-122.
131. Zhang, J., Dawson, V. L., Dawson, T. M., & Snyder, S. H. (1994). Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science, 263, 687-689.